Results from a randomized placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Despite advancements, recurrent Clostridium difficile infections (CDI) remain an urgent public health threat with insufficient response rates to currently approved antibiotic therapies. Microbiota-based treatments appear effective, but rigorous clinical trials are required to optimize dosing strategies and substantiate long-term safety. Methods: This randomized, double-blind, placebo-controlled phase 2B trial enrolled adults with 2 or more CDI recurrences to receive: 2 doses of RBX2660, a standardized microbiota-based drug (group A); 2doses of placebo (group B); or 1 dose of RBX2660 followed by 1 dose of placebo (group C). Efficacy was defined as prevention of recurrent CDI for 8 weeks following treatment. Participants who had a recurrence within 8 weeks were eligible to receive up to 2 open-label RBX2660 doses. The primary endpoint was efficacy for group A compared to group B. Secondary endpoints included the efficacy of group C compared to group B, combined efficacy in the blinded and open-label phases, and safety for 24 months. Results: The efficacy for groups A, B, and C were 61%, 45%, and 67%, respectively. The primary endpoint was not met (P = .152). One RBX2660 dose (group C) was superior to placebo (group B; P = .048), and the overall efficacy (including open-label response) for RBX2660-treated participants was 88.8%. Adverse events did not differ significantly among treatment groups. Conclusions: One, but not 2, doses of RBX2660 was superior to placebo in this randomized, placebo-controlled trial. These data provide important insights for a larger phase 3 trial and continued clinical development of RBX2660. Clinical Trials Registration: NCT02299570.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the efficacy of retention enema had been once doubted, Orenstein and Dubberke et al. have proven it more efficient and safe than placebo in phase I and phase II recurrent CDI clinical trials.64,65”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationMicrobiota-mediated colonization resistance against intestinal pathogens
Buffie, C. G., & Pamer, E. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3535 · Cited by 1,564
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Self-citationBezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Self-citationEmergence of Clostridium difficile-associated disease in North America and Europe
Kuijper, E. J., Coignard, B., & Tüll, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01580.x · Cited by 855
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
Lee, C. H., Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., et al. (2016) · JAMA · doi:10.1001/jama.2015.18098 · Cited by 627
Self-citationKelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., Abd, M., Alani, M., Bakow, B., Curran, P., McKenney, J., Tisch, A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0271 · Cited by 613
Crobach, M. J. T., Planche, T., Eckert, C., Barbut, F., Terveer, E. M., Dekkers, O. M., Wilcox, M. H., & Kuijper, E. J. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.03.010 · Cited by 596
Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era
Polage, C. R., Gyorke, C. E., Kennedy, M. A., Leslie, J. L., Chin, D. L., Wang, S., Nguyen, H. H., Huang, B., Tang, Y.-W., Lee, L. W., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4114 · Cited by 593
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
Vollaard, E. J., & Clasener, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.409 · Cited by 478
Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile
Britton, R. A., & Young, V. B. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.059 · Cited by 446
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Carey-Ann, B. D., & Carroll, K. C. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-13 · Cited by 423
Can we identify patients at high risk of recurrent Clostridium difficile infection?
Kelly, C. P. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12046 · Cited by 396
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I., & Wilt, T. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2693 · Cited by 371
Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., Lombardo, M.-J., Vulic, M., Ohsumi, T., Winkler, J., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv766 · Cited by 321
Self-citationClostridium difficile and the microbiota
Seekatz, A. M., & Young, V. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72336 · Cited by 255
Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ938 · Cited by 197
Self-citationAdverse events in faecal microbiota transplant: a review of the literature
Baxter, M., & Colville, A. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.10.024 · Cited by 185
The Morbidity, Mortality, and Costs Associated with Clostridium difficile Infection
Kwon, J. H., Olsen, M. A., & Dubberke, E. R. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.003 · Cited by 178
Self-citationRecurrent Clostridium difficile infection is associated with increased mortality
Olsen, M. A., Yan, Y., Reske, K. A., Zilberberg, M. D., & Dubberke, E. R. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.08.017 · Cited by 177
Self-citationMa, G. K., Brensinger, C. M., Wu, Q., & Lewis, J. D. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2733 · Cited by 175
Hirsch, B. E., Saraiya, N., Poeth, K., Schwartz, R. M., Epstein, M. E., & Honig, G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0930-z · Cited by 150
Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection
Sheitoyan-Pesant, C., Chakra, C. N. A., Pépin, J., Marcil-Héguy, A., Nault, V., & Valiquette, L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ958 · Cited by 144
Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant
Baxter, M., Ahmad, T., Colville, A., & Sheridan, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ247 · Cited by 126
Impact of Clostridium difficile recurrence on hospital readmissions
Olsen, M. A. A., Yan, Y., Reske, K. A., Zilberberg, M. D., & Dubberke, E. R. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2014.12.020 · Cited by 56
Self-citationAttributable Inpatient Costs of RecurrentClostridium difficileInfections
Dubberke, E. R., Schaefer, É., Reske, K. A., Zilberberg, M. D., Hollenbeak, C. S., & Olsen, M. A. A. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/678428 · Cited by 46
Self-citationMcDonald, J. R., Liang, S. Y., Li, P., Maalouf, S., Murray, C. K., Weintrob, A., Schnaubelt, E. R., Kuhn, J., Ganesan, A., Bradley, W. P. L., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy280 · Cited by 28
Ray, A., & Jones, C. R. (2016) · Future Microbiology · doi:10.2217/fmb.16.10 · Cited by 23
Cited by
Antibiotic resistance: a rundown of a global crisis
Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., Nisar, M. A., Alvi, R. F., Aslam, M. A., Qamar, M. U., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173867 · Cited by 2,552
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Sorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Metadata
- Authors
- Dubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N.
- Affiliations
- Washington University in St. Louis (US)
- Island Health (CA)
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Loyola University Medical Center (US)
- Edward Hines, Jr. VA Hospital (US)
- Corresponding author
- Dubberke, Erik R
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-03-29
- Volume
- 67
- Issue
- 8
- Pages
- 1198-1204
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2795021885
- Cited by
- 140
- References
- 37
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 21 · 2023: 20 · 2022: 19 · 2021: 18 · 2020: 21 · 2019: 16 · 2018: 4
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Rebiotix Inc.
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- RBX2660, recurrent Clostridium difficile infection, microbiota-based therapy, fecal microbiota transplantation, dosing regimen, treatment efficacy, drug safety, adverse events
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Biological Therapy, Clostridium Infections, Diarrhea, Double-Blind Method, Enterocolitis, Pseudomembranous, Feces, Female, Humans, Male, Middle Aged, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.